c‐MYC activation impairs the NF‐κB and the interferon response: Implications for the pathogenesis of Burkitt's lymphoma
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Deregulation of the proto‐oncogene c‐myc is a key event in the pathogenesis of many tumors. A paradigm is the activation of the c‐myc gene by chromosomal translocations in Burkitt lymphoma (BL). Despite expression of a restricted set of Epstein–Barr viral (EBV) antigens, BL cells are not recognized by antigen‐specific cytotoxic T cells (CTLs) because of their inability to process and present HLA class I‐restricted antigens. In contrast, cells of EBV‐driven posttransplant lymphoproliferative disease (PTLD) are recognized and rejected by EBV‐specific CTLs. It is not known whether the poor immunogenicity of BL cells is due to nonexpression of viral antigens, overexpression of c‐myc, or both. To understand the basis for immune recognition and escape, we have compared the mRNA expression profiles of BL and EBV‐immortalized cells (as PTLD model). Among the genes expressed at low level in BL cells, we have identified many genes involved in the NF‐κB and interferon response that play a pivotal role in antigen presentation and immune recognition. Using a cell line in which EBNA2 and c‐myc can be regulated at will, we show that c‐MYC negatively regulates STAT1, the central player linking the Type‐I and Type‐II interferon response. Switching off c‐myc expression leads to STAT1 induction through a direct and indirect mechanism involving induction of Type‐I interferons. c‐MYC thus masks an interferon‐inducing activity in these cells. Our findings imply that immune escape of tumor cells is not only a matter of in vivo selection but may be additionally promoted by activation of a cellular oncogene. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465 · cited 1×
“of IRF1 increases the susceptibility to tumor development of mice with a mutated c-Ha-ras transgene or p53 nullizygosity,(51) and STAT1 deletion accelerates tumor development in p53 mice.(52) Takaoka et al.”
BackgroundTakaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847
Holtschke, T., Löhler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer, F., Lou, J., Knobeloch, K.-P., Gabriele, L., Waring, J. F., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81348-3 · Cited by 644 · cited 1×
“, who showed that ICSBP (IRF8) mice develop a chronic myeloid leukemialike syndrome.(49) Remarkably, IRF1 but not IRF1 cells, can be transformed in vitro by a mutated ras oncogene.”
BackgroundTanaka, N., Ishihara, M., Kitagawa, M., Harada, H., Kimura, T., Matsuyama, T., Lamphier, M. S., Aizawa, S., Mak, T. W., & Taniguchi, T. (1994) · Cell · doi:10.1016/0092-8674(94)90132-5 · Cited by 491
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Ablasser, A., Bauernfeind, F., Hartmann, G., Latz, E., Fitzgerald, K. A., & Hornung, V. (2009) · Nature Immunology · doi:10.1038/ni.1779 · Cited by 893
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
Immunogenic effects of chemotherapy-induced tumor cell death
Wang, Y.-J., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 314
The curious case of the tumour virus: 50 years of Burkitt's lymphoma
Thorley-Lawson, D. A., & Allday, M. J. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro2015 · Cited by 282
Metadata
- Authors
- Schlee, M., Hölzel, M., Bernard, S., Mailhammer, R., Schuhmacher, M., Reschke, J., Eick, D., Marinkovic, D., Wirth, T., Rosenwald, A., Staudt, L. M., Eilers, M., Baran‐Marszak, F., Fagard, R., Feuillard, J., Laux, G., & Bornkamm, G. W.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2007-01-30
- Volume
- 120
- Issue
- 7
- Pages
- 1387-1395
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2077438559
- Cited by
- 89
- References
- 6
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.